Subscribe for email alerts

Don’t miss a single Science & Enterprise post. Sign up for our daily email alerts.

Donate to Science & Enterprise

Please share Science & Enterprise

Gut-Brain Meds Developer Going Public in Merger

Milk splashing

(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)

31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger

Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors

Breast tumor microenvironment

Research with lab animals shows an experimental cancer vaccine generates immune-system cells that infiltrate solid tumors and reduce the tumor’s protective environment. . . . → Read More: Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors

Immunotherapy Start-Up Launches Collaboration, Raises $65M

T-cells and cancer cells

A new biotechnology company is creating cancer immunotherapies that it says harness more of the full power of T-cells in the immune system to attack tumors. . . . → Read More: Immunotherapy Start-Up Launches Collaboration, Raises $65M

Grant Funds Regenerative Gel for Treating Skin Ulcers

Antoni Ribas

A California state research agency is funding preclinical development of a gel designed to regenerate stem cells in the skin to help heal venous skin ulcers. . . . → Read More: Grant Funds Regenerative Gel for Treating Skin Ulcers

Hydrogel Biomaterials Company Raises $3M in Early Funds

Trivia Frazier

A developer of bioactive hydrogels as alternatives to animal models for drug discovery and clinical lab tests is raising $3 million in its first venture round. . . . → Read More: Hydrogel Biomaterials Company Raises $3M in Early Funds

RNA Cancer Immunotherapy Shown Feasible in Preclinical Test

Lung cancer illustration

Tests with lab animals show synthetic viral RNA particles, encased in natural oils, can safely invoke an immune response to attack solid tumors. . . . → Read More: RNA Cancer Immunotherapy Shown Feasible in Preclinical Test

Nasal Spray Vaccines Get CEPI, NIH Funding

Nasal spray

A developer of infectious disease vaccines is gaining funds for new nasal sprays protecting against a range of coronaviruses and the sexually-transmitted disease gonorrhea. . . . → Read More: Nasal Spray Vaccines Get CEPI, NIH Funding

Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test

Malaria clinic

A vaccine grown in genetically-altered algae, designed as a nasal-spray and edible drug, is shown to protect lab mice against parasite infections causing malaria. . . . → Read More: Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test

Company Formed to Boost Clinical Trial Success Odds

Human machine interface

A pharma/tech industry group is starting a new company to use algorithms for finding gaps in preclinical data that can impair clinical trial progress. . . . → Read More: Company Formed to Boost Clinical Trial Success Odds

Challenge Seeks Animal-Free Testing for Precision Meds.

Bioprinting

A charitable foundation promoting research on human longevity unveiled a challenge competition to develop animal-free testing for personalized medicine. . . . → Read More: Challenge Seeks Animal-Free Testing for Precision Meds.